Colorectal Cancer Coverage from Every Angle
Advertisement
Advertisement

Jeffrey A. Meyerhardt, MD, MPH: What’s Next for Celecoxib Plus FOLFOX in Advanced Colon Cancer?

Posted: Saturday, May 30, 2020

Jeffrey A. Meyerhardt, MD, MPH, of Dana-Farber Cancer Institute, discusses the clinical implications of data from the CALGB/SWOG 80702 trial, which showed that adding celecoxib to standard chemotherapy did not significantly improve disease-free or overall survival.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.
Advertisement
Advertisement